Up 61% in 2021, why the Race Oncology (ASX:RAC) share price is marching higher again

The Race Oncology (ASX:RAC) share price marched higher today and is now up more than 60% in 2021. We look at the company's latest results.

| More on:

Should you invest $1,000 in Anteris Technologies Ltd right now?

Before you buy Anteris Technologies Ltd shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Anteris Technologies Ltd wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hot on the heels of yesterday's gains, Race Oncology Ltd (ASX: RAC) shares were marching higher again today. By the market's close, the Race Oncology share price had jumped 2.27% to $3.15. That puts the total gains for the company's shares at more than 61% so far in 2021.

Let's take a look at the positive early preclinical ovarian cancer results announced by the company yesterday.

What did the company report?

In an ASX release yesterday morning, Race Oncology reported that early results indicate its cancer-fighting chemotherapeutic agent, Bisantrene, is effective in killing patient-derived ovarian cancer cell lines. Bisantrene killed cancer cells that were resistant to cisplatin, 5-fluorouracil and chlorambucil (the current standard of care ovarian cancer drugs).

Race Oncology is collaborating on the preclinical research program with The University of Newcastle. The research aims to identify Bisantrene's usefulness in treating ovarian cancer. Nikki Verrills of the Hunter Medical Research Institute is spearheading the project.

Ovarian cancer is the fifth most common cause of cancer-related death among women and the most lethal gynaecological malignancy in developed countries.

Commenting on the results Race Oncology CSO Daniel Tillett said:

These initial results from Nikki's team further highlight Bisantrene's potential use in ovarian cancer patients as a safer alternative to the commonly used anthracyclines which can be very dangerous to the hearts of patients. It is highly encouraging that Bisantrene is able to kill ovarian cancer cells resistant to currently used treatments and these findings support further exploration of the use of Bisantrene in ovarian cancer patients.

The company's CEO Phillip Lynch added:

This program is further evidence of Race delivering against the Three Pillar strategy, taking counsel, and completing feasibility assessments with a view to mapping promising yet attainable clinical paths for Bisantrene.

Race Oncology has planned additional trials to confirm Bisantrene's efficacy.

Race Oncology share price snapshot

Over the past 12 months, the Race Oncology share price has surged an eye-popping 703%. That compares to a 0.1% loss on the All Ordinaries Index (ASX: XAO).

Year to date, Race Oncology shares are up by around 61%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares returned to positive territory this Tuesday.

Read more »

Multiple percentage signs in the palm of a man's hand.
Share Market News

ASX 200 lifts on the RBA's latest interest rate call

The ASX 200 is up 0.5% on the heels of the RBA’s interest rate announcement.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Macquarie tips 40% upside for this ASX 200 real estate stock

Let's see what the broker is saying about this stock.

Read more »

Woman sits at her desk working at night, while traffic flows on a busy freeway out the window behind her.
Broker Notes

Transurban shares: Buy, hold, sell? Here's Macquarie's recommendation

Macquarie’s analysts just ran their slide rules over Transurban shares. Here’s what they found.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Consumer Staples & Discretionary Shares

Which 'enduring high-quality business' has become a forgotten ASX 200 stock?

Fundie says this ASX 200 consumer discretionary stock has been flying under investors' radar.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Financial Shares

Want a financial stock outside the big 4 banks? Macquarie tips 15% upside for this small cap financial

For those searching on the edges, this name could be worth a second look according to Macquarie.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today

Why are these shares taking a tumble today? Let's find out.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Breville, Clarity, EOS, and TechnologyOne shares are racing higher today

These shares are having a strong session on Tuesday. But why?

Read more »